Anterogen Co., Ltd.
Quick facts
| Founded | 2000 |
|---|
Marketed products
- ASC · Regenerative Medicine
ASC is an autologous stem cell therapy that promotes tissue regeneration and repair through the patient's own stem cells.
Phase 3 pipeline
- ALLO-ASC-DFU · Dermatology / Wound Care
ALLO-ASC-DFU is an allogeneic adipose-derived mesenchymal stem cell therapy that promotes wound healing and tissue regeneration in diabetic foot ulcers. - Fibringlue · Other
Phase 2 pipeline
- Adipocell · Other
- ADIPOPLUS · Diabetes
ADIPOPLUS is a small molecule that targets the SIRT1 pathway to enhance adipocyte function and glucose metabolism. - ALLO-ASC-CD
Allogeneic adipose-derived stem cells that may modulate immune responses and promote tissue repair through paracrine signaling. - ALLO-ASC-SHEET
Allogeneic adipose-derived stem cell sheet that may provide regenerative effects through paracrine signaling and tissue repair mechanisms.
Phase 1 pipeline
- ALLO-ASC-TI
Allogeneic adipose-derived mesenchymal stem cells with potential immunomodulatory and tissue regenerative properties. - ANT-301
- Repaircell · Other
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Anterogen Co., Ltd.
What are Anterogen Co., Ltd.'s marketed drugs?
Top marketed products include ASC.
What is Anterogen Co., Ltd.'s pipeline?
Anterogen Co., Ltd. has 2 drugs in Phase 3, 4 in Phase 2, 3 in Phase 1. Late-stage candidates include ALLO-ASC-DFU, Fibringlue.
When was Anterogen Co., Ltd. founded?
Anterogen Co., Ltd. was founded in 2000.
Related
- ASC · Regenerative Medicine
- Sector hub: All tracked pharma companies